Related Experiment Videos
[Roles of PPARs in carcinogenesis]
Kazuhiro Imamura1, Jie Lu, Michio Kaminishi
1Department of Gastrointestinal Surgery, Surgical Science, Graduate School of Medicine, The University of Tokyo.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 15, 2005
Summary
Peroxisome proliferator activated receptor gamma (PPARgamma) inhibits gastric cancer development. Its ligand, troglitazone, shows chemopreventive potential, but new, safer ligands are needed for clinical use.
Area of Science:
- Molecular biology
- Oncology
- Pharmacology
Context:
- Peroxisome proliferator activated receptors (PPARs) are implicated in various cancers.
- The specific roles of PPARalpha and PPAR delta in carcinogenesis remain unclear.
- PPARgamma is increasingly recognized as an inhibitor of carcinogenesis.
Purpose:
- To investigate the role of PPARgamma in gastric carcinogenesis.
- To evaluate PPARgamma ligands as potential chemopreventive agents for gastric cancer.
- To confirm the PPARgamma-dependent effects of chemoprevention using PPARgamma knockout mice.
Summary:
- PPARgamma activation suppresses gastric carcinogenesis.
- The PPARgamma ligand troglitazone demonstrated chemopreventive effects against gastric cancer.
- These protective effects were confirmed to be dependent on PPARgamma expression.
Impact:
- This study highlights PPARgamma's tumor-suppressive function in the gastric system.
- Troglitazone emerges as a potential chemopreventive strategy for gastric cancer.
- The findings underscore the need for developing more selective and potent PPARgamma ligands to overcome clinical limitations associated with current drugs like thiazolidinediones due to side effects.